pirinixic acid has been researched along with Disease Models, Animal in 46 studies
pirinixic acid: structure
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " EXPERIMENTAL APPROACH We determined the effect of LP105, a pirinixic acid derivative which acts as inhibitor of 5-LOX, COX and mPGES-1, on aortic aneurysm development in mice and on 5-LOX activity in murine monocytes." | 7.77 | A pirinixic acid derivative (LP105) inhibits murine 5-lipoxygenase activity and attenuates vascular remodelling in a murine model of aortic aneurysm. ( Brandes, RP; Fischer, AS; Geisslinger, G; Maier, TJ; Mieth, A; Paulke, A; Pellowska, M; Popescu, L; Revermann, M; Schermuly, RT; Schubert-Zsilavecz, M; Steinhilber, D; Steri, R; Wurglics, M, 2011) |
| " The aim of this study was to investigate the capacity of chiglitazar to improve insulin resistance and dyslipidemia in monosodium L-glutamate (MSG) obese rats and to determine whether its lipid-lowering effect is mediated through its activation of PPARalpha." | 7.73 | The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. ( Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ, 2006) |
| " Langendorff-perfused hearts of rats pretreated with the selective PPAR-α agonist WY-14643 (WY, pirinixic acid; 3 mg·(kg body mass)·day(-1); 5 days) were subjected to 30 min ischaemia - 2 h reperfusion with or without the phosphatidylinositol 3-kinase (PI3K)-Akt inhibitor wortmannin for the evaluation of functional (left ventricular developed pressure, LVDP) recovery, infarct size (IS), and reperfusion-induced arrhythmias." | 3.78 | PPAR-alpha activation as a preconditioning-like intervention in rats in vivo confers myocardial protection against acute ischaemia-reperfusion injury: involvement of PI3K-Akt. ( Adameová, A; Barlaka, E; Carnická, S; Galatou, E; Kelly, T; Khandelwal, VK; Lazou, A; Ledvényiová, V; Nemčeková, M; Ravingerová, T, 2012) |
| " EXPERIMENTAL APPROACH We determined the effect of LP105, a pirinixic acid derivative which acts as inhibitor of 5-LOX, COX and mPGES-1, on aortic aneurysm development in mice and on 5-LOX activity in murine monocytes." | 3.77 | A pirinixic acid derivative (LP105) inhibits murine 5-lipoxygenase activity and attenuates vascular remodelling in a murine model of aortic aneurysm. ( Brandes, RP; Fischer, AS; Geisslinger, G; Maier, TJ; Mieth, A; Paulke, A; Pellowska, M; Popescu, L; Revermann, M; Schermuly, RT; Schubert-Zsilavecz, M; Steinhilber, D; Steri, R; Wurglics, M, 2011) |
| " The aim of this study was to investigate the capacity of chiglitazar to improve insulin resistance and dyslipidemia in monosodium L-glutamate (MSG) obese rats and to determine whether its lipid-lowering effect is mediated through its activation of PPARalpha." | 3.73 | The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. ( Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ, 2006) |
| "This study was designed to investigate the effects of two, chemically distinct activators of PPAR-a (clofibrate and WY14643) in a rat model of acute myocardial infarction." | 3.71 | Ligands of the peroxisome proliferator-activated receptor-PPAR-a reduce myocardial infarct size. ( Ellis, BL; Thiemermann, C; Wayman, NS, 2002) |
| "PPARα activation induces hepatomegaly and plays an important role in liver regeneration, but the underlying mechanisms remain unclear." | 1.72 | YAP-TEAD mediates PPAR α-induced hepatomegaly and liver regeneration in mice. ( Bi, H; Fan, S; Gao, Y; Gonzalez, FJ; Huang, M; Jiang, Y; Li, H; Qu, A; Tian, J; Wang, R; Xie, G; Yagai, T; Yang, X; Yao, X; Zhu, S, 2022) |
| "Hypertension is associated with endothelial dysfunction, which favors the release of endothelium-derived contracting factors, including vasoconstrictor prostanoids and reactive oxygen species." | 1.48 | PPAR-α agonists acutely inhibit Ca ( Chen, H; Leung, SWS; Man, RYK, 2018) |
| "To evaluate PPARα activation in nicotine dependence we used the selective and potent PPARα agonist, WY-14643 and the clinically used PPARα activator, fenofibrate, in nicotine CPP and we observed attenuation of nicotine preference, but fenofibrate was less potent." | 1.46 | In vivo interactions between α7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-α: Implication for nicotine dependence. ( Bagdas, D; Carroll, FI; Damaj, MI; Greenwald, M; Jackson, A; Lichtman, AH; Miles, MF; Muldoon, PP, 2017) |
| "Pulmonary hypertension is a fatal disease; however, its pathogenesis still remains to be elucidated." | 1.46 | Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target. ( Al-Mamun, E; Kikuchi, N; Kurosawa, R; Miyata, S; Morser, J; Nogi, M; Numano, K; Omura, J; Satoh, K; Satoh, T; Shimokawa, H; Siddique, MA; Sunamura, S; Suzuki, K; Yaoita, N, 2017) |
| " Many factors contribute to dilated cardiomyopathy, for instance, long-term use of doxorubicin, one of the anthracyclines clinically used for cancer chemotherapy, result in dilated cardiomyopathy and congestive heart failure." | 1.42 | Effects of PPARα/PGC-1α on the energy metabolism remodeling and apoptosis in the doxorubicin induced mice cardiomyocytes in vitro. ( Jiang, Q; Li, X; Yang, T; Yang, Y; Zhang, H, 2015) |
| "Perfluorooctanoic acid (PFOA) is an environmental contaminant known to induce developmental toxicity in animal models through activation of the peroxisome proliferator-activated receptor α (PPARα)." | 1.39 | Perfluorooctanoic acid induced-developmental cardiotoxicity: are peroxisome proliferator activated receptor α (PPARα) and bone morphorgenic protein 2 (BMP2) pathways involved? ( DeWitt, JC; Jiang, Q; Lust, RM, 2013) |
| "Acute pancreatitis was induced in rats by administration of cerulein." | 1.39 | Attenuation of acute pancreatitis by peroxisome proliferator-activated receptor-α in rats: the effect on Toll-like receptor signaling pathways. ( Ding, JL; Li, Y; Sun, XF; Wang, L; Wang, R; Zhan, L; Zhou, B; Zhou, XY; Zhou, ZG, 2013) |
| "Indomethacin was less effective, though tissue prostaglandin E2 but not leukotriene B4 levels were reduced." | 1.33 | The peroxisome proliferator-activated receptor alpha activator, Wy14,643, is anti-inflammatory in vivo. ( Andrews, G; Colville-Nash, P; Freemantle, C; Lam, C; Papworth, J; Willis, D; Willoughby, D, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (41.30) | 29.6817 |
| 2010's | 24 (52.17) | 24.3611 |
| 2020's | 3 (6.52) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Z | 1 |
| Liao, C | 1 |
| Ko, BC | 1 |
| Shan, S | 2 |
| Tong, EH | 1 |
| Yin, Z | 1 |
| Pan, D | 1 |
| Wong, VK | 1 |
| Shi, L | 1 |
| Ning, ZQ | 2 |
| Hu, W | 2 |
| Zhou, J | 1 |
| Chung, SS | 1 |
| Lu, XP | 2 |
| Makadia, P | 1 |
| Shah, SR | 1 |
| Pingali, H | 1 |
| Zaware, P | 1 |
| Patel, D | 1 |
| Pola, S | 1 |
| Thube, B | 1 |
| Priyadarshini, P | 1 |
| Suthar, D | 1 |
| Shah, M | 1 |
| Giri, S | 1 |
| Trivedi, C | 1 |
| Jain, M | 1 |
| Patel, P | 1 |
| Bahekar, R | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Xue, Y | 1 |
| Guo, C | 1 |
| Hu, F | 1 |
| Zhu, W | 1 |
| Mao, S | 1 |
| Fan, S | 1 |
| Gao, Y | 1 |
| Qu, A | 1 |
| Jiang, Y | 1 |
| Li, H | 1 |
| Xie, G | 1 |
| Yao, X | 1 |
| Yang, X | 1 |
| Zhu, S | 1 |
| Yagai, T | 1 |
| Tian, J | 1 |
| Wang, R | 2 |
| Gonzalez, FJ | 3 |
| Huang, M | 1 |
| Bi, H | 1 |
| Chen, H | 1 |
| Man, RYK | 1 |
| Leung, SWS | 1 |
| Zhou, Y | 1 |
| Chen, X | 2 |
| Qu, N | 1 |
| Zhang, B | 1 |
| Xia, C | 1 |
| Jiang, Q | 2 |
| Lust, RM | 1 |
| DeWitt, JC | 1 |
| Nemčeková, M | 2 |
| Čarnická, S | 2 |
| Ferko, M | 1 |
| Muráriková, M | 1 |
| Ledvényiová, V | 2 |
| Ravingerová, T | 2 |
| Skrypnyk, N | 1 |
| Su, Y | 1 |
| Mont, S | 1 |
| Yang, S | 1 |
| Gangadhariah, M | 1 |
| Wei, S | 1 |
| Falck, JR | 1 |
| Jat, JL | 1 |
| Zent, R | 1 |
| Capdevila, JH | 1 |
| Pozzi, A | 1 |
| Jiao, M | 1 |
| Ren, F | 1 |
| Zhou, L | 2 |
| Zhang, X | 2 |
| Zhang, L | 1 |
| Wen, T | 1 |
| Wei, L | 1 |
| Wang, X | 1 |
| Shi, H | 1 |
| Bai, L | 1 |
| Zheng, S | 1 |
| Zhang, J | 1 |
| Chen, Y | 1 |
| Han, Y | 1 |
| Zhao, C | 1 |
| Duan, Z | 1 |
| Yang, Y | 1 |
| Zhang, H | 1 |
| Li, X | 1 |
| Yang, T | 1 |
| Xu, H | 1 |
| You, Z | 1 |
| Wu, Z | 1 |
| Shen, J | 1 |
| Gu, Z | 1 |
| Fang, ZZ | 1 |
| Tanaka, N | 1 |
| Lu, D | 1 |
| Jiang, CT | 1 |
| Zhang, WH | 1 |
| Zhang, C | 1 |
| Du, Z | 1 |
| Fu, ZW | 1 |
| Gao, P | 1 |
| Cao, YF | 1 |
| Sun, HZ | 1 |
| Zhu, ZT | 1 |
| Cai, Y | 1 |
| Krausz, KW | 2 |
| Yao, Z | 1 |
| Kaimoto, S | 1 |
| Hoshino, A | 1 |
| Ariyoshi, M | 1 |
| Okawa, Y | 1 |
| Tateishi, S | 1 |
| Ono, K | 1 |
| Uchihashi, M | 1 |
| Fukai, K | 1 |
| Iwai-Kanai, E | 1 |
| Matoba, S | 1 |
| Jackson, A | 1 |
| Bagdas, D | 1 |
| Muldoon, PP | 1 |
| Lichtman, AH | 1 |
| Carroll, FI | 1 |
| Greenwald, M | 1 |
| Miles, MF | 1 |
| Damaj, MI | 1 |
| Satoh, T | 1 |
| Satoh, K | 1 |
| Yaoita, N | 1 |
| Kikuchi, N | 1 |
| Omura, J | 1 |
| Kurosawa, R | 1 |
| Numano, K | 1 |
| Al-Mamun, E | 1 |
| Siddique, MA | 1 |
| Sunamura, S | 1 |
| Nogi, M | 1 |
| Suzuki, K | 1 |
| Miyata, S | 1 |
| Morser, J | 1 |
| Shimokawa, H | 1 |
| Schaefer, MB | 1 |
| Pose, A | 1 |
| Ott, J | 1 |
| Hecker, M | 1 |
| Behnk, A | 1 |
| Schulz, R | 1 |
| Weissmann, N | 1 |
| Günther, A | 1 |
| Seeger, W | 1 |
| Mayer, K | 1 |
| Xu, SQ | 1 |
| Li, YH | 1 |
| Hu, SH | 1 |
| Chen, K | 1 |
| Dong, LY | 1 |
| Bulhak, AA | 1 |
| Jung, C | 1 |
| Ostenson, CG | 1 |
| Lundberg, JO | 1 |
| Sjöquist, PO | 1 |
| Pernow, J | 1 |
| Cho, WS | 1 |
| Jeong, J | 1 |
| Choi, M | 1 |
| Park, SN | 1 |
| Han, BS | 1 |
| Son, WC | 1 |
| Chen, R | 1 |
| Liang, F | 1 |
| Morimoto, S | 1 |
| Li, Q | 1 |
| Moriya, J | 1 |
| Yamakawa, J | 1 |
| Takahashi, T | 1 |
| Iwai, K | 1 |
| Kanda, T | 1 |
| Wang, G | 1 |
| Namura, S | 1 |
| Revermann, M | 1 |
| Mieth, A | 1 |
| Popescu, L | 1 |
| Paulke, A | 1 |
| Wurglics, M | 1 |
| Pellowska, M | 1 |
| Fischer, AS | 1 |
| Steri, R | 1 |
| Maier, TJ | 1 |
| Schermuly, RT | 1 |
| Geisslinger, G | 1 |
| Schubert-Zsilavecz, M | 1 |
| Brandes, RP | 1 |
| Steinhilber, D | 1 |
| Hatano, Y | 1 |
| Elias, PM | 1 |
| Crumrine, D | 1 |
| Feingold, KR | 1 |
| Katagiri, K | 1 |
| Fujiwara, S | 1 |
| Azuma, YT | 1 |
| Nishiyama, K | 1 |
| Morioka, A | 1 |
| Nakajima, H | 1 |
| Takeuchi, T | 1 |
| Larter, CZ | 1 |
| Yeh, MM | 1 |
| Van Rooyen, DM | 1 |
| Brooling, J | 1 |
| Ghatora, K | 1 |
| Farrell, GC | 1 |
| Patterson, AD | 1 |
| Shah, YM | 1 |
| Matsubara, T | 1 |
| Chiba, T | 1 |
| Takeuchi, S | 1 |
| Esaki, H | 1 |
| Yamamura, K | 1 |
| Kurihara, Y | 1 |
| Moroi, Y | 1 |
| Furue, M | 1 |
| Ding, JL | 1 |
| Zhou, ZG | 1 |
| Zhou, XY | 1 |
| Zhou, B | 1 |
| Wang, L | 1 |
| Zhan, L | 1 |
| Sun, XF | 1 |
| Li, Y | 1 |
| Adameová, A | 1 |
| Kelly, T | 1 |
| Barlaka, E | 1 |
| Galatou, E | 1 |
| Khandelwal, VK | 1 |
| Lazou, A | 1 |
| Wayman, NS | 1 |
| Ellis, BL | 1 |
| Thiemermann, C | 1 |
| Holness, MJ | 1 |
| Bulmer, K | 1 |
| Smith, ND | 1 |
| Sugden, MC | 1 |
| Hironaka, K | 1 |
| Factor, VM | 1 |
| Calvisi, DF | 1 |
| Conner, EA | 1 |
| Thorgeirsson, SS | 1 |
| Stavinoha, MA | 1 |
| RaySpellicy, JW | 1 |
| Essop, MF | 1 |
| Graveleau, C | 1 |
| Abel, ED | 1 |
| Hart-Sailors, ML | 1 |
| Mersmann, HJ | 1 |
| Bray, MS | 1 |
| Young, ME | 1 |
| Bates, CM | 1 |
| Lin, F | 1 |
| Amacher, DE | 1 |
| Adler, R | 1 |
| Herath, A | 1 |
| Townsend, RR | 1 |
| Colville-Nash, P | 1 |
| Willis, D | 1 |
| Papworth, J | 1 |
| Freemantle, C | 1 |
| Lam, C | 1 |
| Andrews, G | 1 |
| Willoughby, D | 1 |
| Li, PP | 1 |
| Chen, YT | 1 |
| Sun, SJ | 1 |
| Liu, Q | 1 |
| Xie, MZ | 1 |
| Shen, ZF | 1 |
| Jiang, P | 1 |
| Wang, JC | 1 |
| Zhao, YM | 1 |
| Qian, GS | 1 |
| Suardíaz, M | 1 |
| Estivill-Torrús, G | 1 |
| Goicoechea, C | 1 |
| Bilbao, A | 1 |
| Rodríguez de Fonseca, F | 1 |
| Zahradka, P | 1 |
| Lelliott, CJ | 1 |
| Ljungberg, A | 1 |
| Ahnmark, A | 1 |
| William-Olsson, L | 1 |
| Ekroos, K | 1 |
| Elmgren, A | 1 |
| Arnerup, G | 1 |
| Shoulders, CC | 1 |
| Oscarsson, J | 1 |
| Lindén, D | 1 |
| Staumont-Sallé, D | 1 |
| Abboud, G | 1 |
| Brénuchon, C | 1 |
| Kanda, A | 1 |
| Roumier, T | 1 |
| Lavogiez, C | 1 |
| Fleury, S | 1 |
| Rémy, P | 1 |
| Papin, JP | 1 |
| Bertrand-Michel, J | 1 |
| Tercé, F | 1 |
| Staels, B | 1 |
| Delaporte, E | 1 |
| Capron, M | 1 |
| Dombrowicz, D | 1 |
| Toyoda, T | 1 |
| Kamei, Y | 1 |
| Kato, H | 1 |
| Sugita, S | 1 |
| Takeya, M | 1 |
| Suganami, T | 1 |
| Ogawa, Y | 1 |
| Taylor, BK | 1 |
| Dadia, N | 1 |
| Yang, CB | 1 |
| Krishnan, S | 1 |
| Badr, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396] | Phase 2 | 701 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fenofibrate + Usual Care | 19 |
| Placebo + Usual Care | 22 |
The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.03 |
| Placebo + Usual Care | 5.03 |
Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Median) |
|---|---|
| Fenofibrate + Usual Care | 30 |
| Placebo + Usual Care | 30 |
Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Mean) |
|---|---|
| Fenofibrate + Usual Care | 28.8 |
| Placebo + Usual Care | 28.3 |
The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days
| Intervention | Ranked Severity Score (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.32 |
| Placebo + Usual Care | 5.33 |
The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.05 |
| Placebo + Usual Care | 5.05 |
A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 1 |
| Placebo + Usual Care | 1 |
2 reviews available for pirinixic acid and Disease Models, Animal
| Article | Year |
|---|---|
Future strategies in the treatment of acute renal failure: growth factors, stem cells, and other novel therapies.
Topics: Acetylcysteine; Acute Kidney Injury; Animals; Atrial Natriuretic Factor; Disease Models, Animal; Hem | 2005 |
Cardiovascular actions of the peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist Wy14,643.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Cardiovascular System; Disease Models, Animal; Hu | 2007 |
44 other studies available for pirinixic acid and Disease Models, Animal
| Article | Year |
|---|---|
Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.
Topics: Adipose Tissue; Administration, Oral; Aldehydes; Animals; Blood Glucose; Diabetes Mellitus, Type 2; | 2004 |
Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.
Topics: Animals; Cricetinae; Disease Models, Animal; Ether; Hep G2 Cells; Humans; Hypoglycemic Agents; Male; | 2011 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
PPARA/RXRA signalling regulates the fate of hepatic non-esterified fatty acids in a sheep model of maternal undernutrition.
Topics: 3-Hydroxybutyric Acid; Alitretinoin; Animals; Disease Models, Animal; Fatty Acids, Nonesterified; Fe | 2020 |
YAP-TEAD mediates PPAR α-induced hepatomegaly and liver regeneration in mice.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Gene Expression Regulation; Gene Knockdown Tech | 2022 |
PPAR-α agonists acutely inhibit Ca
Topics: Animals; Antihypertensive Agents; Antioxidants; Aorta; Disease Models, Animal; Fenofibrate; Hydrogen | 2018 |
Chondroprotection of PPARα activation by WY14643 via autophagy involving Akt and ERK in LPS-treated mouse chondrocytes and osteoarthritis model.
Topics: Animals; Anticholesteremic Agents; Autophagy; Cartilage, Articular; Chondrocytes; Disease Models, An | 2019 |
Perfluorooctanoic acid induced-developmental cardiotoxicity: are peroxisome proliferator activated receptor α (PPARα) and bone morphorgenic protein 2 (BMP2) pathways involved?
Topics: Animals; Biomarkers; Bone Morphogenetic Protein 2; Caprylates; Chick Embryo; Disease Models, Animal; | 2013 |
Treatment of rats with hypolipidemic compound pirinixic acid protects their hearts against ischemic injury: are mitochondrial K(ATP) channels and reactive oxygen species involved?
Topics: Animals; Cardiotonic Agents; Cytoprotection; Disease Models, Animal; Hypolipidemic Agents; Lipid Per | 2013 |
PPARα activation can help prevent and treat non-small cell lung cancer.
Topics: Animals; Arachidonic Acids; Bezafibrate; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Prol | 2014 |
Peroxisome proliferator-activated receptor α activation attenuates the inflammatory response to protect the liver from acute failure by promoting the autophagy pathway.
Topics: Acute Disease; Adenine; Adult; Animals; Autophagy; Autophagy-Related Protein 7; Cells, Cultured; Che | 2014 |
Effects of PPARα/PGC-1α on the energy metabolism remodeling and apoptosis in the doxorubicin induced mice cardiomyocytes in vitro.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Biomarkers; Cell Proliferation; Disease Models, Ani | 2015 |
WY14643 Attenuates the Scopolamine-Induced Memory Impairments in Mice.
Topics: Animals; Avoidance Learning; Brain-Derived Neurotrophic Factor; Cognition; Disease Models, Animal; H | 2016 |
Role of the lipid-regulated NF-κB/IL-6/STAT3 axis in alpha-naphthyl isothiocyanate-induced liver injury.
Topics: 1-Naphthylisothiocyanate; Animals; Chemical and Drug Induced Liver Injury; Disease Models, Animal; I | 2017 |
Activation of PPAR-α in the early stage of heart failure maintained myocardial function and energetics in pressure-overload heart failure.
Topics: Animals; Aorta; Blotting, Western; Disease Models, Animal; Echocardiography; Energy Metabolism; Fatt | 2017 |
In vivo interactions between α7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-α: Implication for nicotine dependence.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Anesthetics, Local; Animals; Benzamides; Bridged Bicyclo Co | 2017 |
Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target.
Topics: Adult; Animals; Arterial Pressure; Capillary Permeability; Carboxypeptidase B2; Case-Control Studies | 2017 |
Peroxisome proliferator-activated receptor-alpha reduces inflammation and vascular leakage in a murine model of acute lung injury.
Topics: Acute Lung Injury; Animals; Capillaries; Disease Models, Animal; Endotoxins; Inflammation; Lipopolys | 2008 |
Effects of Wy14643 on hepatic ischemia reperfusion injury in rats.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Disease Models, Animal; Hepatitis; Inter | 2008 |
PPAR-alpha activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-Kinase/Akt and NO pathway.
Topics: Androstadienes; Animals; Blood Glucose; Body Weight; Cardiotonic Agents; Diabetes Mellitus, Type 2; | 2009 |
26-Week carcinogenicity study of di-isodecyl phthalate by dietary administration to CB6F1-rasH2 transgenic mice.
Topics: Adenoma, Liver Cell; Administration, Oral; Animals; Carcinogenicity Tests; Carcinogens; Clofibrate; | 2011 |
The effects of a PPARalpha agonist on myocardial damage in obese diabetic mice with heart failure.
Topics: Adiponectin; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Heart Failure; Mice | 2010 |
Effects of chronic systemic treatment with peroxisome proliferator-activated receptor α activators on neuroinflammation induced by intracerebral injection of lipopolysaccharide in adult mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Disease Models, Animal; Fenofibrate; Fibric | 2011 |
A pirinixic acid derivative (LP105) inhibits murine 5-lipoxygenase activity and attenuates vascular remodelling in a murine model of aortic aneurysm.
Topics: Administration, Oral; Angiotensin II; Animals; Aorta; Aortic Aneurysm; Arachidonate 5-Lipoxygenase; | 2011 |
Efficacy of combined peroxisome proliferator-activated receptor-α ligand and glucocorticoid therapy in a murine model of atopic dermatitis.
Topics: Adjuvants, Immunologic; Animals; Clobetasol; Dermatitis, Atopic; Disease Models, Animal; Drug Synerg | 2011 |
Clofibrate relaxes the longitudinal smooth muscle of the mouse distal colon through calcium-mediated desensitisation of contractile machinery.
Topics: Anilides; Animals; Anticholesteremic Agents; Benzamides; Calcium; Clofibrate; Colon; Cyclic AMP-Depe | 2011 |
Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Topics: Adipose Tissue; Animals; Blotting, Western; Chemokine CCL2; Diabetes Mellitus; Disease Models, Anima | 2012 |
Peroxisome proliferator-activated receptor alpha induction of uncoupling protein 2 protects against acetaminophen-induced liver toxicity.
Topics: Acetaminophen; Analysis of Variance; Animals; Blotting, Western; Chemical and Drug Induced Liver Inj | 2012 |
Topical application of PPARα (but not β/δ or γ) suppresses atopic dermatitis in NC/Nga mice.
Topics: Animals; Dermatitis, Atopic; Disease Models, Animal; Eosinophils; Epidermis; Female; Immunoglobulin | 2012 |
Attenuation of acute pancreatitis by peroxisome proliferator-activated receptor-α in rats: the effect on Toll-like receptor signaling pathways.
Topics: Amylases; Animals; Anti-Inflammatory Agents; Biomarkers; Blotting, Western; Calcium; Ceruletide; Cyt | 2013 |
PPAR-alpha activation as a preconditioning-like intervention in rats in vivo confers myocardial protection against acute ischaemia-reperfusion injury: involvement of PI3K-Akt.
Topics: Androstadienes; Animals; Arrhythmias, Cardiac; Chymases; Disease Models, Animal; Male; Myocardial In | 2012 |
Ligands of the peroxisome proliferator-activated receptor-PPAR-a reduce myocardial infarct size.
Topics: Animals; Cardiotonic Agents; Clofibrate; Disease Models, Animal; Heart; Hemodynamics; Ligands; Male; | 2002 |
Investigation of potential mechanisms regulating protein expression of hepatic pyruvate dehydrogenase kinase isoforms 2 and 4 by fatty acids and thyroid hormone.
Topics: Animals; Carnitine O-Palmitoyltransferase; Disease Models, Animal; Fatty Acids; Female; Hyperthyroid | 2003 |
Dysregulation of DNA repair pathways in a transforming growth factor alpha/c-myc transgenic mouse model of accelerated hepatocarcinogenesis.
Topics: Animals; Disease Models, Animal; DNA Damage; DNA Repair; Gene Expression Regulation; Genes, myc; Hep | 2003 |
Evidence for mitochondrial thioesterase 1 as a peroxisome proliferator-activated receptor-alpha-regulated gene in cardiac and skeletal muscle.
Topics: Animals; Blood Pressure; Carrier Proteins; Cells, Cultured; Circadian Rhythm; Diabetes Mellitus, Exp | 2004 |
Use of proteomic methods to identify serum biomarkers associated with rat liver toxicity or hypertrophy.
Topics: 1-Naphthylisothiocyanate; Acetaminophen; Animals; Biomarkers; Chemical and Drug Induced Liver Injury | 2005 |
The peroxisome proliferator-activated receptor alpha activator, Wy14,643, is anti-inflammatory in vivo.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Arachidonate 5-Lipoxygenase; Dinoprostone; | 2005 |
The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Carbazoles; Disease Models, Animal; Dyslipidemias; Gene Expr | 2006 |
[Influence and mechanism of peroxisome proliferation activated receptor-alpha expression induced by WY14643 in rat lung with acute lung injury].
Topics: Acute Lung Injury; Animals; Disease Models, Animal; Lung; Male; Peroxisome Proliferators; PPAR alpha | 2006 |
Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain.
Topics: Analgesics; Animals; Anticholesteremic Agents; Behavior, Animal; Disease Models, Animal; Dizocilpine | 2007 |
Hepatic PGC-1beta overexpression induces combined hyperlipidemia and modulates the response to PPARalpha activation.
Topics: Acetyl-CoA Carboxylase; Adenoviridae; Animals; Anticholesteremic Agents; Apolipoproteins B; CD36 Ant | 2007 |
Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis.
Topics: Administration, Cutaneous; Administration, Topical; Adult; Animals; Bronchial Hyperreactivity; Derma | 2008 |
Effect of peroxisome proliferator-activated receptor-alpha ligands in the interaction between adipocytes and macrophages in obese adipose tissue.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Anti-Inflammatory Agents; Cell Communication; Cell Line; Chemokin | 2008 |
Peroxisome proliferator-activated receptor agonists inhibit inflammatory edema and hyperalgesia.
Topics: Animals; Carrageenan; Disease Models, Animal; Edema; Hyperalgesia; Inflammation; Ligands; Male; Pero | 2002 |